2018 was a record year for biotech and pharma. According to data from the NVCA/Pitchbook, VC across all sectors topped $130B invested across nearly 9000 deals – the first time the industry has broken the $100B barrier since the dot-com era.
Many investors in this industry tend to be well-educated life-science focused VCs or corporate science guru’s that understand the nuances of the business. Backing some of the larger, already-established companies, Novartis, Pfizer, GlaxoSmithkline, and Novo Nordisk are just a few of the most active pharma investors in the industry.
Provided the difficulty of assessing the fundamental science behind a pharma company in conjunction with managing inherent regulatory blockades, and designing expensive clinical trials, startups in this competitive space often require significant funding just to get their feet wet–with no guarantee that their product will be a success.
One company with exciting potential and preparing for a clinical trial is Propanc Biopharma, Inc. (“PPCBD”). Propanc is a biopharmaceutical company focused on the development of long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer.
Their lead product, PRP, is a prospective cancer-treatment revolution. It’s a patented, formulation consisting of two proenzymes mixed in a synergistic ratio that targets solid tumors. The Company’s initial target patient populations include pancreatic, ovarian and colorectal cancers.
Today we are highlighting: Propanc BioPharma, Inc. (OTCQB: PPCBD), Sernova Corp. (OTCQB: SEOVF), Heat Biologics, Inc. (NASDAQ: HTBX), Sophiris Bio, Inc. (NASDAQ: SPHS), Regulus Therapeutics Inc. (NASDAQ: RGLS).
Propanc BioPharma, Inc. (OTCQB: PPCBD), (Market Cap: $N/A, Share price: $2.76); Propanc BioPharma, Inc. is a clinical stage biopharmaceutical company focusing on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, recently announced it had completed a scientific advice meeting with the MHRA in reference to the company’s lead product PRP which has been designated as an Orphan Drug by the FDA for Pancreatic Cancer. Additionally the company went through a number of topics regarding the Clinical Trial Application for PRP, and the first in human studies that the company plans to conduct in the UK for its lead product PRP. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergistic ratio that targets solid tumors.
Sernova Corp. (OTCQB: SEOVF), (Market Cap: $28.982M, Share price: $0.17); Sernova Corp. is a regenerative medicine therapeutics company, focused on developing and commercializing its proprietary implantable prevascularized medical device technologies: the Cell PouchTM and associated technologies including therapeutic cells and local immune protection. The Cell Pouch is a scalable, implantable, medical device, designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells. These cells, following transplantation into the implanted device vascularized environment, release proteins, hormones or other factors into the bloodstream for the long-term treatment of a number of serious, chronic diseases such as diabetes, hemophilia and thyroid disease.
Heat Biologics, Inc. (NASDAQ: HTBX), (Market Cap: $23.505M, Share price: $0.69); Heat Biologics is a biopharmaceutical company developing therapies designed to activate a patient’s immune system against cancer. The company announced on June 3rd a compelling new interim results from its ongoing Phase 2 study investigating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®).
Sophiris Bio, Inc. (NASDAQ: SPHS), (Market Cap: $28.697M, Share price: $0.9497);
Sophiris Bio is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. Once activated, topsalysin self-aggregates to form stable transmembrane pores and initiate cell death. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.
Regulus Therapeutics Inc. (NASDAQ: RGLS), (Market Cap: $27.619M, Share price: $1.33); Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program.
As record deals are being made in an industry that is filled with an abundance of opportunity and innovation, already established companies with a strong product pipeline and proven track record, like Propanc Biopharma, Inc. are a safe bet in terms of obtaining a solid return on investment.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting expects to be paid $3,000 for the article directly from PPCB. All payments were made directly by Propanc Biopharma, Inc. (PPCB) to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. PPCB was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Full Legal Disclaimer Click Here.
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Country: United States